GlassScriptPhysician profile
Shiva Nallur
NPI 1780706663
$3,179.44
in general payments reported to CMS, 2019-2025
31 companies · $618 in 2025
The $618 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $55.76 · 2021: $315 · 2022: $269 · 2023: $643 · 2024: $878 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631.86 | 2021-2025 | |
| Amgen INC. | $448.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $338.39 | 2019-2025 | |
| Lilly USA, LLC | $265.97 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $264.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $156.56 | 2019-2024 | Gardasil, Gardasil 9, Vaxelis |
| Novo Nordisk INC | $143.77 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $76.85 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.22 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $68.10 | 2022-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $64.29 | 2019 | |
| Esperion Therapeutics, INC. | $64.20 | 2023 | Nexletol |
| Exact Sciences Corporation | $61.88 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.62 | 2019-2024 | |
| Astellas Pharma US INC | $52.28 | 2024-2025 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.42 | 2023-2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $36.18 | 2021-2022 | |
| Sanofi Pasteur INC. | $35.57 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $35.08 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $32.47 | 2021-2024 | Zoryve |
| Shield Therapeutics INC | $30.52 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $30.48 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $24.88 | 2021 | |
| Boston Scientific Corporation | $24.60 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.44 | 2024 | Caplyta |
| Tris Pharma INC | $21.01 | 2025 | Dyanavel Xr |
| Hologic Sales and Service, LLC | $15.96 | 2021 | |
| Currax Pharmaceuticals LLC | $15.26 | 2025 | Onzetra Xsail, Contrave |
| Abbott Laboratories | $14.93 | 2023 | Freestyle Libre 3 |
| Allergan, INC. | $14.49 | 2019 | |
| Shire North American Group INC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiva Nallur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.